Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness

Blood

Volumn 103, Issue 1, 2004, Pages 333-339

  Seftel, Matthew D ^b   Growe, Gershon H ^b   Petraszko, Tanya ^b   Benny, W Barrett ^b   Le, Alan ^b   Lee, Chao Yong ^b   Spinelli, John J ^b   Sutherland, Heather J ^b   Tsang, Peter ^b   Hogge, Donna E ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE LEUKEMIA; ADULT; ALLOIMMUNIZATION; ARTICLE; BLOOD TRANSFUSION; CANADA; FEMALE; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; THROMBOCYTE PRESERVATION; UNIVERSAL PRESTORAGE LEUKOREDUCTION;

EID: 9144229557     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-03-0940     Document Type: Article

References (44)

1. Schiffer C, Dutcher JP, Aisner A, Hogge D, Wiernik PH, Reilly JP. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood. 1983;62:815-820.
2. Andreu G, Dewailly J, Leberre C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood. 1988;72:964-969.
3. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood. 1988;71:1402-1407.
4. Oksanen K, Kekomaki R, Ruutu T, Koskimies S, Myllyla G. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components - a randomized trial. Transfusion. 1991;31:588-594.
5. Van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JW. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood. 1991;77:201-205.
6. Williamson LM, Wimperis JZ, Williamson P, et al. Bedside filtration of blood products in the prevention of HLA alloimmunization - a prospective, randomized study. Blood. 1994;83:3028-3035.
7. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. New Eng J Med. 1997;337:1861-1869.
8. Sintnicolaas K, Van Marwijk Kooy M, van Prooijen HC, et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood. 1995;85:824-828.
9. Eernisse JG, Brand A. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. Exp Hematol. 1981;9:77-83.
10. Murphy MF, Metcalfe P, Thomas H, et al. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol. 1986;62:529-534.
11. Schiffer CA. Diagnosis and management of refractoriness to platelet transfusion. Blood Rev. 2001;15:175-180.
12. Hogge DE, McConnell M, Jacobson C, Sutherland HJ, Benny WB, Massing BG. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients. Transfusion. 1995;35:645-652.
13. Welsh KI, Burgos H, Batchelor JR. The immune response to allogeneic rat platelets; Ag-B antigens in matrix form lacking Ia. Eur J Immunol. 1977;7:267-272.
14. Kekornaki S, Volin L, Koistinen P, et al. Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia. Eur J Haematol. 1998;60:112-118.
15. Vamvakas EC. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Transfus Med. 1998;12:258-270.
16. Muller-Steimhardt M, Schlenke P, Wagner T, Kluter H. Transfusion of platelet concentrates from pooled buffy-coats: comparison of bedside vs. prestorage leukofiltration. Transfus Med. 2000;10:59-65.
17. Novotny VM, van Doom R, Witvliet MD, Claas FH, Brand A. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood. 1995;85:1736-1741.
18. Blajchman, MA, Bardossy L, Carmen RA, Goldman M, Heddle NM, Singal DP. An animal model of allogeneic donor platelet refractoriness: the effect of the time of leukodepletion. Blood. 1992;79:1371-1375.
19. Kao KJ, Mickel M, Braine HG, et al. White cell reduction in platelet concentrates and packed red cells by filtration: a multicenter clinical trial: the Trap Study Group. Transfusion. 1995;35:13-19.
20. Popovsky MA. Quality of blood components filtered before storage and at the bedside: implications for transfusion practice. Transfusion. 1996;36:470-474.
21. Gibis B, Baladi JF. Leukoreduction: the techniques used, their effectiveness and costs. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1998.
22. Vamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. Transfusion. 2001;41:691-712.
23. Goodnough LT. The case against universal WBC reduction (and for the practice of evidence-based medicine). Transfusion. 2000;40:1522-1527.
24. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med. 1997;337:1870-1875.
25. 9/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91:3601-3606.
26. Duquesnoy RJ, Filip DJ, Rodey GE, Rimm AA, Aster RH. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol. 1977;2:219-226.
27. Brand A, Van Leeuwen A, Eemisse JG, van Rood JJ. Platelet transfusion therapy: optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence tests. Blood. 1978;51:781-788.
28. Mittal KK, Mickey MR, Singal DP, Terasaki PI. Serotyping for homotransplantation: 18. refinement of microdroplet lymphocyte cytotoxicity test. Transplantation. 1968;6:913-927.
29. Hogge DE, Dutcher JP, Aisner J, Schiffer CA. Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. Am J Hematol. 1983;14:363-369.
30. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley; 1989.
31. Gmur J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet. 1991;338:1223-1226.
32. Vamvakas EC, Blajchman MA. Prestorage versus poststorage white cell reduction for the prevention of the deleterious immunomodulatory effects of allogeneic blood transfusion. Transfus Med Rev. 2000;14:23-33.
33. Engelfriet CP, Reesink HW, Pietersz RN, et al. Universal leucocyte-depletion of blood components: cell concentrates and plasma. Vox Sang. 2001;81:56-77.
34. Toor AA, Choo SY, Little JA. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplant. 2000;26:315-320.
35. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1519-1538.
36. Heddle NM, Klama L, Meyer R, et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion. 1999;39:231-238.
37. Heddle NM, Klama LN, Griffith L, Roberts R, Shukla G, Kelton JG. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion. 1993;33:794-797.
38. Muir JC, Jacobson S, Herschel L, AuBuchon JP. Does prestorage leukocyte reduction of blood components reduce the risk of febrile reactions in sensitized patients [abstract]? Blood. 1994;84:464a.
39. Uhlmann EJ, Isgriggs E, Wallhermtechtel M, Goodnough LT. Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion. 2001;41:997-1000.
40. Heddle NM, Blajchman MA, Meyer RM, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion. 2002;42:556-566.
41. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86:3598-3603.
42. van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation. 1998;97:562-568.
43. Ratko TA, Cummings JP, Oberman HA, et al. Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion. 2001;41:1310-1319.
44. Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003;101:4195-4200.